Influence of Prostate Artery Embolization on Different Qualities of Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction.

Autor: Theurich AT; Department of Urology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany., Leistritz L; Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany., Leucht K; Department of Urology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany., Franiel T; Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany., Teichgräber U; Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany., Foller S; Department of Urology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany., Grimm MO; Department of Urology, Friedrich-Schiller University, Jena University Hospital, Jena, Germany. Electronic address: marc-oliver.grimm@med.uni-jena.de.
Jazyk: angličtina
Zdroj: European urology focus [Eur Urol Focus] 2022 Sep; Vol. 8 (5), pp. 1323-1330. Date of Electronic Publication: 2022 Feb 04.
DOI: 10.1016/j.euf.2022.01.011
Abstrakt: Background: Prostate artery embolization (PAE) is an increasingly used minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic obstruction (BPO) OBJECTIVE: To analyze the impact of PAE on voiding and storage symptoms.
Design, Setting, and Participants: Between July 2014 and May 2019, 351 consecutive men with BPO who underwent PAE were included in a single-center study.
Intervention: PAE is an interventional radiological procedure embolizing the prostatic arteries with microspheres.
Outcome Measurements and Statistical Analysis: The primary endpoint represented assessment of the International Prostatic Symptom Score (IPSS) at baseline and at 1, 3, 6, 12, and 24 mo after PAE. Secondary endpoints comprised assessment of IPSS quality of life (QoL), International Index of Erectile Function, peak urinary flow rate, postvoid residual volume, prostate volume, and prostate-specific antigen at the same time points. Data were analyzed using standard statistical methods, generalized estimating equations (symptom improvement over time as odds ratios), and McNemar-Bowker test (degree of improvement compared between symptoms).
Results and Limitations: Clinical success rates for PAE were 68%, 73%, and 66% at 1, 12, and 24 mo, respectively. The median IPSS improved significantly from 22 to 10 points after 2 yr (p < 0.001). Storage (-50%) and voiding (-58%) symptoms improved similarly (each p < 0.001), with nocturia decreasing least frequently but significantly (p < 0.001). After 1 and 2 yr, 35% (95% confidence interval [CI] 29-41%) and 30% (95% CI 21-40%) of patients reported alleviated storage, and 39% (95% CI 33-45%) and 38% (95% CI 29-49%) reported alleviated voiding symptoms, respectively. QoL improved from 5 to 2 points (p < 0.001). The main limitation is the number of patients lost during follow-up.
Conclusions: PAE significantly improved voiding and storage symptoms to a similar extent. This study may aid in counseling patients about this minimally invasive BPO treatment.
Patient Summary: Prostate artery embolization (PAE) is a minimally invasive treatment option for patients with voiding and storage symptoms from benign prostate enlargement. Our analysis shows that PAE improves relevant lower urinary tract symptoms.
(Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: